Browse the evidence

Genetic susceptibility to common obesity is distributed across a mosaic of specific neuronal cell types in the brain (including hypothalamus, midbrain, and cortex) rather than being driven by a single canonical energy homeostasis circuit.

This research suggests that obesity is not caused by a single broken part in the brain but involves a complex network of neurons across multiple regions. This implies that treatments targeting only one area (like the hypothalamus) might be insufficient for everyone, and future therapies may need to address this broader neural network.

Tribulus Terrestris supplementation does not improve muscle strength, body composition, or testosterone levels in trained individuals, despite marketing claims to the contrary.

Do not take Tribulus Terrestris expecting it to increase your testosterone or muscle strength. Research shows it has no effect on these metrics in trained individuals. It is likely a waste of money, though it may have a placebo effect.

Vitamin D3 supplementation does not significantly improve arterial stiffness, as measured by pulse wave velocity (PWV) or augmentation index (AI).

Do not expect vitamin D3 supplementation to directly improve arterial stiffness (PWV or AI). While it may help lower blood pressure and cholesterol, it does not appear to change the physical stiffness of your arteries. Manage arterial health through exercise, blood pressure control, and other lifestyle factors.

The improvement in endothelial function resulting from exercise training is significantly attenuated (weakened) in patients with type 2 diabetes compared to non-diabetic individuals.

Even though your blood vessels may not improve as much as a healthy person's after starting an exercise routine, you still gain significant vascular benefits. Do not let the 'blunted response' discourage you; the absolute improvement in endothelial function is still clinically important for reducing cardiovascular risk.

Sleep pharmaceuticals (e.g., zolpidem, eszopiclone) used by military personnel can reduce short-term and long-term neurobehavioral performance, particularly in attention and reaction time.

Avoid using prescription sleep aids like Ambien or Lunesta if possible, as they can impair your performance the next day. Instead, seek cognitive-behavioral therapy for insomnia (CBT-I) or practice good sleep hygiene. If you must use medication, ensure you have at least 8 hours of non-work time afterward.

Supplementation with Lactobacillus gasseri or Lactobacillus johnsonii attenuates western diet-induced type 2 diabetes phenotypes in mice by improving hepatic mitochondrial health and reducing liver lipid accumulation.

If you are at risk for type 2 diabetes due to a high-sugar/high-fat diet, specific strains of Lactobacillus (L. gasseri and L. johnsonii) may help protect your liver's ability to process fats and manage blood sugar. They work by improving the health of liver mitochondria and increasing protective antioxidants like glutathione, rather than by changing your gut bacteria. This suggests that targeting liver health via specific probiotics could be a strategy for metabolic prevention.

Bariatric surgery (specifically Roux-en-Y gastric bypass and sleeve gastrectomy) resets the body fat set point to a lower level, resulting in sustained weight loss and reduced hunger through physiological mechanisms rather than simple caloric restriction.

For individuals with severe obesity who have struggled to maintain weight loss through diet and exercise alone, bariatric surgery offers a physiological reset of hunger and satiety signals. This biological change supports long-term weight maintenance more effectively than willpower-based dietary restriction alone, though it requires lifelong nutritional monitoring.

Insulin resistance in NAFLD creates a paradoxical state where insulin fails to suppress hepatic glucose production (causing hyperglycemia) while simultaneously stimulating de novo lipogenesis (causing hepatic steatosis).

If you have fatty liver, your body's insulin signaling is broken in a specific way: your liver ignores insulin's command to stop making sugar, but it still obeys insulin's command to make fat. This means standard 'low insulin' strategies might not address the root cause if they don't improve the specific insulin signaling pathway (PI3K-AKT) in the liver. Focus on improving overall insulin sensitivity through lifestyle changes rather than just avoiding insulin-producing foods.

Metformin (1,500 mg) acutely increases postprandial GLP-1 secretion in patients with type 2 diabetes, contributing approximately 75% to its glucose-lowering effect via direct AMPK-dependent activation of intestinal L cells.

For patients with type 2 diabetes, taking metformin (typically 1,500 mg) with a meal triggers the release of GLP-1, a gut hormone that helps lower blood sugar. This gut-mediated effect accounts for a large portion (approx. 75%) of metformin's immediate glucose-lowering benefit. This mechanism is direct, dependent on AMPK activation in gut cells, and preserved in obese patients and those with diabetes.

Male sex is associated with higher cardiorespiratory fitness (CRF) compared to female sex.

On average, men have higher cardiorespiratory fitness than women. This is a biological difference, not a measure of worth. Regardless of sex, improving your fitness through activity is crucial for health. Focus on your own progress rather than comparing yourself to the opposite sex.

Age-related decline in α-Klotho expression in muscle progenitor cells drives mitochondrial dysfunction and impaired muscle regeneration.

Maintaining or boosting α-Klotho levels may support muscle repair as you age. While direct supplementation isn't a standard consumer product yet, understanding this pathway highlights the importance of factors that support mitochondrial health and hormonal balance in aging.

Supplementation with exogenous α-Klotho restores mitochondrial DNA integrity and bioenergetics in aged muscle progenitor cells, enhancing functional regeneration.

Exogenous α-Klotho supplementation shows promise in restoring muscle regeneration in aged models by fixing mitochondrial function. This suggests potential future therapies for age-related muscle loss.

Dietary resistant starch (RS) improves insulin sensitivity and reduces plasma insulin levels independently of the gut microbiota, likely through modulation of bile acid profiles and reduction of adipose tissue macrophage infiltration.

If you are trying to improve insulin sensitivity, adding resistant starch (like cooled potatoes, green bananas, or specific supplements like Hi-Maize) to your diet can help, even if you haven't focused on probiotics or prebiotics for your gut bacteria. The study used a 10% replacement of starch with RS in a high-fat diet context. For humans, this translates to incorporating RS-rich foods into meals, particularly those high in refined carbs or fats, to potentially lower fasting insulin levels through direct metabolic pathways involving bile acids and reduced inflammation in fat tissue.

Disruption of cardiolipin synthesis in thermogenic fat leads to insulin resistance and reduced metabolic flexibility through a mechanism involving ER stress factor CHOP-10.

This finding highlights that brown fat health is not just about burning calories but also about signaling. Disrupting this signaling (via lack of cardiolipin) can lead to insulin resistance. This suggests that preserving brown fat function through lifestyle factors like cold exposure might help maintain insulin sensitivity.

Past exposure to violence victimization (adolescent or childhood) exacerbates the negative association between loneliness and sleep quality.

If you have a history of violence or maltreatment, loneliness may hit your sleep harder than it does for others. This is likely due to heightened threat sensitivity. Interventions should address both the social connection and the trauma history, as treating one without the other may be less effective.

Insulin resistance is the central pathogenic mechanism linking Metabolic Syndrome and NAFLD, driven by visceral adipose tissue expansion and the resulting release of free fatty acids and adipokines.

Fatty liver is not just about fat in the liver; it is a symptom of insulin resistance caused by visceral fat. Treating the underlying insulin resistance through weight loss and exercise is more effective than targeting liver fat alone.

Endurance exercise significantly increases circulating beta-hydroxybutyrate (BHBA), which acts as a signaling molecule that inhibits histone deacetylases (HDACs) and activates the HCA2 receptor, promoting anti-inflammatory and neuroprotective effects.

Endurance exercise naturally boosts BHBA, which helps protect your brain and reduce inflammation. You don't need to force a ketogenic diet to get these benefits; regular aerobic activity is sufficient to trigger this protective signaling pathway.

Bariatric surgery is the most effective treatment for both obesity and T2DM, offering benefits beyond weight loss by recovering islet function and normalizing gut hormones.

For severe obesity and T2DM, bariatric surgery is currently the most effective treatment, working by restoring gut hormones (GLP-1, PYY) and beta-cell function, not just by reducing stomach size. It should be considered when lifestyle changes fail, despite surgical risks.

A bimodal GLP-1/MK-801 conjugate produces synergistic weight loss and metabolic improvements in diet-induced obese rodents by targeting NMDA receptors in GLP-1-expressing brain regions, while mitigating the adverse behavioral and physiological effects of MK-801 monotherapy.

This research describes a new experimental drug that combines two mechanisms to treat obesity in animals. It works by targeting specific brain cells to reduce food intake and increase energy expenditure without the side effects of older drugs. This is not yet available for humans.

Hepatic overexpression of the enzyme ALOXE3 enhances whole-body insulin sensitivity and reduces weight gain by generating the PPARγ ligand 12-KETE.

This research identifies ALOXE3 as a key enzyme induced by fasting that improves insulin sensitivity by activating PPARγ. While direct supplementation with ALOXE3 is not currently available, the findings suggest that strategies inducing this enzyme, such as fasting or specific glucose transporter blockers (like trehalose), may offer metabolic benefits. Current clinical application is limited as genetic therapy is not yet optimized for polygenic diseases like obesity.

In real-world outpatient settings for Type 2 Diabetes, pharmacological management of blood pressure, HbA1c, and LDL cholesterol achieves target control in only a minority of patients, with combined adequate control of all three factors occurring in just 16.4% of cases.

If you have Type 2 Diabetes, having prescriptions for blood pressure, sugar, and cholesterol medication does not guarantee your body is responding correctly. In this study, only 16% of patients had all three numbers in the safe zone. You must actively monitor your HbA1c, LDL, and Blood Pressure, not just fill your prescriptions. If your numbers are not at target, discuss intensifying or changing your therapy with your doctor.

Sibutramine increases the risk of nonfatal cardiovascular events (myocardial infarction and stroke) in patients with pre-existing cardiovascular disease or type 2 diabetes with additional risk factors, leading to its contraindication in these populations.

If you have heart disease, a history of stroke, or diabetes combined with other heart risks (like high blood pressure or smoking), sibutramine is not safe for you. It increases your chance of having a heart attack or stroke. Do not use this medication if you fall into these categories; consult your doctor for safer alternatives.

Traditional weight management strategies, including lifestyle interventions and metabolic and bariatric surgery (MBS), are generally ineffective for reducing hyperphagia in patients with rare MC4R pathway diseases because they do not address the underlying pathophysiology.

For patients with rare genetic obesity (POMC, LEPR, BBS, etc.), standard diets, exercise programs, and even weight-loss surgery often fail to control the insatiable hunger (hyperphagia). This is not a failure of willpower but a failure of the treatment to address the specific brain signaling defect. Recognizing this can reduce caregiver guilt and shift focus toward seeking targeted genetic therapies.

Selective activation of Gs signaling in enteroendocrine K cells increases endogenous GIP secretion, which improves glucose tolerance in obese and diabetic mouse models.

This research suggests that therapies targeting the specific signaling pathways (Gs) in gut K cells to boost natural GIP production could be a viable strategy for managing obesity and Type 2 Diabetes, potentially offering better glucose control than current approaches that rely on external hormone administration.